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Edited by Sandro SonninoAbstract Exosomes are small vesicles secreted by diﬀerent
immune cells and which display anti-tumoral properties. Stim-
ulation of RBL-2H3 cells with ionomycin triggered phospholi-
pase D2 (PLD2) translocation from plasma membrane to
intracellular compartments and the release of exosomes. Al-
though exosomes carry the two isoforms of PLD, PLD2 was
enriched and speciﬁcally sorted on exosomes when overexpressed
in cells. PLD activity present on exosomes was clearly increased
following PLD2 overexpression. PLD2 activity in cells was
correlated to the amount of exosome released, as measured by
FACS. Therefore, the present work indicates that exosomes can
vehicle signaling enzymes.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.1. Introduction
Phospholipase D (PLD) hydrolyzes phosphatidylcholine to
generate choline and phosphatidic acid (PA). PA is an im-
portant lipid second messenger implicated in many cellular
functions [1], including exocytosis, endocytosis, remodeling of
the actin cytoskeleton, and which also directly activates a
range of target proteins such as mTOR [2]. Since PA is a
fusogenic lipid [3], it has been implicated in diﬀerent steps of
vesicular traﬃcking and intracellular membrane fusion events
[4]. For example, PLD is involved in secretion mechanisms in
granulocytes [5] and RBL mast cells [6]. Also, inhibitors of
serine/threonine kinases that regulate PLD activity suppress
both PLD activity and secretion in these cells [7]. Two main
isoforms of PLD, PLD1 and PLD2, have been characterized,
which are diﬀerently regulated but are both dependent on
phosphatidylinositol-4,5-bisphosphate [1]. PLD1 is activated
by GTPases of ARF family such as Arf1 and of Rho families
(RhoA, cdc42 and Rac), and by protein kinases C. Conversely,* Corresponding author.
E-mail address: record@cict.fr (M. Record).
Abbreviations: BODIPY, 4,4-diﬂuoro-4-bora-3a,4a-diaza-s-indacene;
NBD, 2-6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino; MVB, multivesic-
ular bodies
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Synucleins [8] and actin [9] are known as cellular inhibitors of
PLD2 activity but PLD2 regulation is still unclear. Each iso-
form seems to be diﬀerently localized in cells. PLD1 is present
on intracellular compartments corresponding to granules or
Golgi apparatus [10], whereas PLD2 has been observed pref-
erentially on plasma membrane [6]. Due to its low abundance,
the intracellular localization of PLD2 has been studied only
indirectly through overexpression of chimeric proteins like
GFP-tagged PLD2 [6]. Nevertheless, it has also been shown
that a signiﬁcant fraction of endogenous PLD2 localized to the
perinuclear Golgi region and was also distributed throughout
dense cytoplasmic puncta [11].
We have investigated the role of PLD2 in intracellular ve-
sicular traﬃcking in mast cells and more precisely in the se-
cretion of immuno-active vesicles, exosomes. Exosomes are
small vesicles (60–90 nm) formed in multivesicular bodies
(MVB) and secreted when MVB fuse with plasma membrane
[12]. These vesicles have attracted much interest, since Zitvogel
et al. [13] have shown that dendritic cells-derived exosomes
endowed immune anti-tumoral activities in mice. Clinical trials
are currently in progress.
In the present work, we have observed the enrichment of an
active PLD2 on exosomes secreted by RBL-2H3 cells and
shown that PLD2 was necessary to obtain maximal exosome
secretion.2. Materials and methods
2.1. Chemical reagents and antibodies
RPMI 1640, DMEM, PBS, penicillin, streptomycin and L-glutamine
were purchased from Biowhittaker. FCS was from Gibco (Paisley,
UK). All solvents, alcohols were from Merck Eurolab (VWR). 4,4-
Diﬂuoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-PC and BODIPY-
ceramide (Molecular Probes) were stored in ethanol at )20 C. All
chemical reagents were from Sigma (St. Louis) except glycine (Euro-
bio). Rabbit polyclonal anti-PLD antibody (N-PLD4) was from
Johnson Pharmaceutical Research Institute (Raritan, NJ, USA) and
was kindly supplied by Dr. D. Uhlinger. This antibody was raised
against the sequence 523–537 of human PLD2, which was found 100%
identical with rat PLD2 and 75% identical with rat PLD1. The HA.11
monoclonal mouse anti-HA antibody (clone 16B12) was from BabCo
(Eurogentec). Secondary antibodies labeled with horseradish peroxi-
dase (HRP, goat anti-rabbit) or with rhodamine (goat anti-mouse)ation of European Biochemical Societies.
Fig. 1. (A) Exosomes and RBL-2H3 cells were analyzed by Western
blotting with polyclonal NPLD4 anti-PLD antibody. Rat brain was
used as PLD2 control. (B) Resting and ionomycin-activated RBL cells
overexpressing HA-tagged PLD2 (RBL PLD2+) and exosomes from
RBL PLD2+ were analyzed by Western blotting using NPLD4 or anti-
HA antibodies. (C) HA-tagged PLD2 localization was analyzed by
immuno-ﬂuorescence microscopy in resting or ionomycin-activated
RBL PLD2+ cells. Lower panels in (C) are merge of transmission and
ﬂuorescence.
12 K. Laulagnier et al. / FEBS Letters 572 (2004) 11–14were from Chemicon and Beckman-Coulter, respectively. Methyl
arachidonoyl ﬂuorophosphonate (MAFP) was from Calbiochem.
2.2. Cells
RBL-2H3 cells were grown as previously reported [14]. Cells were
kept either adherent, or in suspension under constant agitation in
spinner bottles (VWR). RBL cells overexpressing active (RBL PLD2+)
or inactive (RBL PLD2)) PLD2 were obtained by electroporation
(250 V, 500 lF) of cells with linearized pcDNA3.1 vector containing
the HA-tagged cDNA of murine PLD2 with a catalytic active or in-
active (K758R) sequence. PLD2 overexpressing cells were selected with
geneticin (500 lg/ml) added in regular cultures, but suppressed in
spinner bottle cultures for exosome preparation.
2.3. Exosomes preparation
Wild type RBL cells, RBL PLD2+ or RBL PLD2), were grown in
suspension and degranulation was triggered with ionomycin (ﬁnal
concentration 1 lM) during 20 min at 37 C. Exosomes were then
recovered and puriﬁed by diﬀerential centrifugations from superna-
tants recovered after stimulation as described [14,15]. The ﬁnal pellet
referred to as exosomes was taken up in PBS for further analyses.
Usually, 300 lg of exosomal proteins [14] was obtained from 1 · 109
RBL Wt cells. Quality of preparations was routinely checked by
electron microscopy (D. Lankar, Institut Curie [15]).
2.4. Cytoﬂuorimetry analysis of in vitro-labeled exosomes
Exosomes were labeled with 4.8 lM BODIPY-ceramide, BODIPY-
PC or 2-6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino (NBD)-PC in PBS
for 30 min at 37 C in the dark. Excess of ﬂuorescent lipids was re-
moved by two successive ultracentrifugations at 110 000· g for 70 min
at 4 C in a TLX100 ultracentrifuge (Beckman Coulter). Pelleted
ﬂuorescent exosomes were taken up in PBS and ﬂuorescence was
measured by spectroﬂuorimetry (kexc ¼ 475 nm; kem ¼ 515 nm).
For FACS analyses, pelleted labeled exosomes were incubated at
room temperature 15 min with 10 ll of aldehyde-sulfate-coated latex
beads (Interfacial, Dynamics Corp., Portland, USA) and then for 1 h
in 1 ml of PBS [15]. Free aldehyde-sulfate groups were then saturated
by 100 mM of glycine for 30 min at room temperature [15]. Beads
carrying ﬂuorescent exosomes were then washed twice in FACS buﬀer
(0.01% NaN2, 1% FCS in PBS) by two centrifugations for 3 min at
2000 rpm and ﬁnally analyzed by FACS with the settings used for
FITC. Fluorescence was proportional to known amounts of exosomes
up to 30 lg proteins.
2.5. Measurement of PLD activity by HPLC
Production of phosphatidylethanol (transphosphatidylation reac-
tion) [1] was monitored by HPLC using ﬂuorescent phosphatidylcho-
line (BODIPY-PC) as PLD substrate. 1· 106 sonicated RBL cells or
100 lg exosomes were incubated, respectively, 30 and 60 min with 1.1
lM of BODIPY-PC and 1% ethanol in 1 ml PBS with 2 mM Caþþ/
Mgþþ, at 37 C with 10 lMMAFP (a phospholipase A2 inhibitor) and
10 ll protease inhibitor cocktail (P8340, Sigma). Then, ﬂuorescent
lipids were extracted with 1 ml butanol-1. Separation of ﬂuorescent
BODIPY-PC-derived products was realized according to the proce-
dure described by Kemken et al. [16].
2.6. Western blotting analyses
Cells and exosomes were lysed in sample buﬀer (80 mM Tris–HCl,
glycerol 10%, SDS 10%, b-mercaptoethanol 2%, w/v; bromophenol
blue 5%, v/v) and sonicated. 40 lg of proteins was then separated on a
6.5% SDS–polyacrylamide gel and transferred on to a nitrocellulose
membrane. Membranes were saturated with 10% non-fat milk in PBS–
0.1% Tween 20 for 1 h at room temperature and blotted with rabbit or
mouse primary antibodies against PLD or HA, respectively, in 1%
non-fat milk in PBS–0.1% Tween 20 at room temperature for 45 min.
Membranes were then washed and incubated in the same buﬀer with
HRP-labeled, anti-rabbit IgG or anti-mouse IgG secondary antibod-
ies. The signal was detected by enhanced chemiluminescence system.
2.7. Immunoﬂuorescence microscopy experiments
Resting RBL PLD2+ cells were grown overnight on glass/Teﬂon
coverslips (VWR) in complete medium (1· 104 cells/50 ll). Cells were
then ﬁxed 20 min with 5% PBS/paraformaldehyde (w/v) at room
temperature, and permeabilized 15 min at room temperature with
0.05% saponin (w/v) in RPMI, 10% BSA (w/v), and 10 mM glycin.Cells were then labeled at room temperature with anti-HA antibody in
PBS for 45 min and washed before incubation with rhodamine-labeled
anti-mouse secondary antibody in PBS for 45 min in the dark. For
labeling of activated cells, cells were plated, stimulated with ionomycin
(15 min, 37 C), and then treated as for resting cells. Samples were
analyzed with a confocal laser scanning microscope (Zeiss LSM510).3. Results
We analyzed PLD isoforms expression on exosomes com-
paratively to parent cells. As shown in Fig. 1A, PLD1 is more
expressed than PLD2 in RBL, whereas on exosomes the two
isoforms are equally expressed, indicating that PLD2 is en-
riched on exosomes compared to total parent cells. We then
overexpressed an HA-tagged PLD2 in RBL and also observed
Fig. 2. (A) Typical chromatograms representatives of ﬂuorescence
HPLC measurement of PLD activity. (B) Quantiﬁcation of PLD spe-
ciﬁc activity on exosomes from WT, PLD2+, PLD2) RBL cells and
corresponding parent cells. Results are means of 2–3 experi-
ments± S.E.M.
Fig. 3. (A) Electron microscopy analysis of exosomes from RBL Wt
cells. Bar¼ 100 nm. (B) Exosomes were labeled with BODIPY-PC,
BODIPY-ceramide or NBD-PC and ﬂuorescence was monitored by
spectroﬂuorimetry (a.u., arbitrary units). (C) BODIPY-ceramide-la-
beled exosomes were loaded on latex beads and analyzed by FACS.
Dot plots showing forward scatter (size) vs. side scatter (content) are
presented. Inset: Exosomes bound on monomeric beads (circled in (A))
were quantiﬁed.
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(Fig. 1B). We next tracked HA-tagged PLD2 in cells by ﬂuo-
rescence microscopy. In resting RBL, HA-PLD2 was located
on the plasma membrane (Fig. 1C, left panels), as already
reported [6]. When degranulation was triggered, we noticed a
redistribution of PLD2 from the plasma membrane towards
the cell interior (Fig. 1C, right panels), which might direct
PLD2 on exosomes.
Exosomes recovered from stimulated RBL Wt contained an
active PLD (Fig. 2) as evidenced by the presence of BODIPY-Fig. 4. (A) FACS quantiﬁcation (a.u.) of BODIPY-ceramide-labeled-exosom
2–3 experiments±S.E.M. are presented. (B) C14-serotonin release by resting
Typical experiment is presented.PEt (Fig. 2A). DG but not PA was noticed on exosomes,
suggesting the presence of a PA-phosphatase. The global PLD
speciﬁc activity (involving both PLD1 and 2) in control Wt
samples was similar in exosomes and parent cells (Fig. 2B). As
compared to Wt samples, overexpression of PLD2 led to a
speciﬁc PLD activity about 10 and ﬁve times higher in exo-
somes and cells, respectively. Overexpression of inactive PLD2
led to about 20% decrease in PLD speciﬁc activity in cells (7.4
vs. 5.5 pmol/mg/h), but no clear eﬀect on exosome PLD ac-
tivity was noticed.
We next investigated whether these modiﬁcations of PLD2
expression and PLD activity in RBL cells could inﬂuence de-
granulation. For this purpose, we improved a previously de-
scribed method to measure the amount of exosomes released
[15]. Quality of exosomes preparation was checked by electron
microscopy. A typical preparation, consistent with previouses released either by WT, RBL PLD2+, or RBL PLD2- cells. Means of
or ionomycin-activated Wt or PLD2+ RBL cells according to time.
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entire population of exosomes independently of any protein
marker, we ﬁrst labeled them with ﬂuorescent lipids. We tested
three ﬂuorescent lipids and observed that the neutral lipid
BODIPY-ceramide was the best marker of exosome mem-
branes (Fig. 3B). Then, labeled exosomes were adsorbed on 3
lM latex beads to be detected by FACS. As shown in Fig. 3C,
monomeric beads (gate A) were mainly represented (74%, in-
set) and FACS analyses were restricted to this population.
As shown in Fig. 4A, PLD2 activity was clearly involved in
exosome release, since about two times more exosomes were
recovered from 4 · 106 RBL PLD2+ and two times less from
4 · 106 RBL PLD2) cells. As expected [6], RBL PLD2+ cells
secreted two times more serotonin than Wt cells (Fig. 4B).4. Discussion
RBL-2H3 cells contain secretory granules corresponding to
MVB [15], able to release upon stimulation their internal
vesicles, called exosomes. Since exosomes trigger immune anti-
tumoral response [13], it is of interest to understand the mo-
lecular mechanisms involved in their biogenesis and secretion.
Diﬀerent steps of secretion and intracellular traﬃcking require
fusogenic lipids such as PA produced by PLD.
In the present work, we have observed a net enrichment of
an active PLD2 isoform on exosomes. Interestingly, PLD2
undergoes intracellular redistribution from the plasma mem-
brane (Fig. 1) upon cell stimulation. A possible PLD2 trans-
location from plasma membrane to secretory granules and
then to exosomes during cell stimulation might account for
exosome enrichment in this enzyme. Noteworthy, PLD2 in-
ternalization from plasma membrane towards intracellular
vesicles has been previously reported [17]. Contamination of
exosome preparations by plasma membrane vesicles can be
ruled out, since exosomes puriﬁed in the same way displayed a
characteristic lipid composition distinct from that of plasma
membrane-derived vesicles [14].
In order to measure the amount of exosome released, we
have adapted a previously described method [15]. In our case,
exosomes were labeled with ﬂuorescent lipids instead of ﬂuo-
rescent antibodies [15]. Short-chain BODIPY-ceramide, a
neutral lipid, was the best tool to label exosome membranes as
compared with NBD-PC and BODIPY-PC (Fig. 3B). This
could be due to the impossibility of NBD-PC, contrarily to
BODIPY-ceramide, to penetrate into liquid-ordered mem-
brane domains with high lateral phospholipid pressure [18,19],
like in exosome membranes [14]. In the same way, intracellular
organelles are diﬀerently labeled with ﬂuorescent lipids de-
pending on their membrane lipid composition and ﬂuidity [20].
As observed in Fig. 4A, overexpression of active or inactive
PLD2 increases or decreases, respectively, exosome release.
Involvement of PLD activity in this process could be related to
the amount of secretory granules, which have fused with the
plasma membrane. Indeed, PLD2 has already been shown to
regulate secretion in RBL-2H3 cells [6]. However, PLD2 could
also participate exosome biogenesis since in syk deﬁcient B
cells, with impaired PLD activation, MVB cannot be ﬁlled
with exosomes [21].In summary, the present work is the ﬁrst report of an active
signaling enzyme present on exosomes. Retrospectively, exos-
omal PLD could account for the noticeable extracellular PLD
activity observed after activation of some cells, such as neu-
trophils [22] or ﬁbroblasts [23]. Finally, PLD activity carried
out by exosomes could be involved either in putative signaling
properties of exosomes through second messengers such as PA,
or in interaction mechanisms between exosomes and target
cells through the fusogenic properties of PA. Exosomes may
thus appear as a new signaling device.
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